{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:26:04Z","timestamp":1753892764544,"version":"3.41.2"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:00:00Z","timestamp":1673568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010822","name":"Chengdu Science and Technology Bureau","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010822","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Hospital-acquired pneumonia (HAP) has a significant and detrimental impact on schizophrenia patients. Non-antipsychotic medicines and modified electroconvulsive therapy (MECT) are frequently used in conjunction with antipsychotics to treat schizophrenia. Whether non-antipsychotic medicines or MECT are risk factors for HAP in schizophrenia treated with antipsychotics is still unknown.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients with schizophrenia who were admitted to the Fourth People's Hospital of Chengdu between January 2015 and April 2022 were included in this retrospective cohort study. Individuals with HAP were 1:1 matched to individuals without HAP (non-HAP) using propensity score matching (PSM). The risk factors for HAP were analyzed by comparing the two groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 7,085 schizophrenia patients were included in this study, with a mean age of 39.77 \u00b1 14.45 years. 193 patients developed HAP on an average of 22.26 \u00b1 21.68 days after admission with an incidence of 2.73%. After 1:1 PSM, 192 patients from each group (HAP and non-HAP) were included. The HAP group had significantly more patients with MECT and taking benzodiazepines, antidepressants, mood stabilizers, and anti-parkinsonians both before and after PSM by <jats:italic>Bonferroni<\/jats:italic> correction (<jats:italic>P<\/jats:italic> &amp;lt; 0.001). Multivariate logistic regression analysis showed that, combined with antipsychotics, non-antipsychotic medicines including benzodiazepines (OR = 3.13, 95%CI = 1.95-5.03, <jats:italic>P<\/jats:italic> &amp;lt; 0.001), mood stabilizers (OR =3.33, 95%CI =1.79\u20136.20, <jats:italic>P<\/jats:italic> &amp;lt; 0.001) and MECT (OR =2.58, 95%CI =1.49\u20134.46, <jats:italic>P<\/jats:italic> = 0.001) were associated with a significantly increased incidence of HAP.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The incidence of HAP in schizophrenia patients in our cohort was 2.73%. MECT and non-antipsychotic medicines, including benzodiazepines and mood stabilizers were risk factors for HAP in schizophrenia patients treated with antipsychotics.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpsyt.2022.1071079","type":"journal-article","created":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T05:13:16Z","timestamp":1673586796000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Non-antipsychotic medicines and modified electroconvulsive therapy are risk factors for hospital-acquired pneumonia in schizophrenia patients"],"prefix":"10.3389","volume":"13","author":[{"given":"Yan","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Di","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiwen","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guocheng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xincheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zipeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Can","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Wan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1080\/13651501.2017.1291839","article-title":"World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of schizophrenia - a short version for primary care","volume":"21","author":"Hasan","year":"2017","journal-title":"Int J Psychiatry Clin Pract."},{"key":"B2","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1177\/0706743717720448","article-title":"Guidelines for the pharmacotherapy of schizophrenia in adults","volume":"62","author":"Remington","year":"2017","journal-title":"Can J Psychiatry."},{"key":"B3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1017\/neu.2018.32","article-title":"in schizophrenia: a review of the evidence","volume":"31","author":"Grover","year":"2019","journal-title":"Acta Neuropsychiatr."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1007\/s40265-021-01556-4","article-title":"Antipsychotic polypharmacy for the management of schizophrenia: evidence and recommendations","volume":"81","author":"L\u00e4hteenvuo","year":"2021","journal-title":"Drugs."},{"key":"B5","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/bcpt.13384","article-title":"Polypharmacy in schizophrenia","volume":"126","author":"Baandrup","year":"2020","journal-title":"Basic Clin Pharmacol Toxicol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.euroneuro.2013.03.001","article-title":"Benzodiazepine augmentation of antipsychotic drugs in schizophrenia: a meta-analysis and Cochrane review of randomized controlled trials","volume":"23","author":"Dold","year":"2013","journal-title":"Eur Neuropsychopharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1176\/appi.ajp.2016.15081035","article-title":"Efficacy and safety of antidepressants added to antipsychotics for schizophrenia: a systematic review and meta-analysis","volume":"173","author":"Helfer","year":"2016","journal-title":"Am J Psychiatry."},{"key":"B8","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/s0924-9338(02)00696-x","article-title":"Antiepileptic drugs in schizophrenia: a review","volume":"17","author":"Hos\u00e1k","year":"2002","journal-title":"Eur Psychiatry."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.schres.2013.02.005","article-title":"Indications for electroconvulsive treatment in schizophrenia: a systematic review","volume":"146","author":"Pompili","year":"2013","journal-title":"Schizophr Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1093\/schbul\/sbab012","article-title":"COVID-19 prevalence and mortality among schizophrenia patients: a large-scale retrospective cohort study","volume":"47","author":"Tzur Bitan","year":"2021","journal-title":"Schizophr Bull."},{"key":"B11","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1001\/jamapsychiatry.2020.4442","article-title":"Association of psychiatric disorders with mortality among patients with COVID-19","volume":"78","author":"Nemani","year":"2021","journal-title":"JAMA Psychiatry."},{"key":"B12","doi-asserted-by":"publisher","first-page":"633","DOI":"10.3949\/ccjm.87a.19117","article-title":"Hospital-acquired and ventilator-associated pneumonia: Diagnosis, management, and prevention","volume":"87","author":"Modi","year":"2020","journal-title":"Cleve Clin J Med."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajic.2022.06.014","article-title":"Risk factors for hospital-acquired pneumonia among inpatients with mental disorders in a large mental health center within a tertiary general hospital","author":"Han","year":"2022","journal-title":"Am J Infect Control"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.746791","article-title":"Influencing factors of hospital-acquired pneumonia infection in the middle-aged and elderly patients with schizophrenia","author":"Yang","year":"2021","journal-title":"Front Psychiatry"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajic.2020.03.010","article-title":"Non-ventilator health care-associated pneumonia (NV-HAP): NV-HAP risk factors","author":"Vignari","year":"2020","journal-title":"Am J Infect Control"},{"key":"B16","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12911-019-0792-1","article-title":"Predicting hospital-acquired pneumonia among schizophrenic patients: a machine learning approach","volume":"19","author":"Kuo","year":"2019","journal-title":"BMC Med Inform Decis Mak"},{"key":"B17","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s40266-020-00754-1","article-title":"Psychotropic drug-associated pneumonia in older adults","volume":"37","author":"Rajamaki","year":"2020","journal-title":"Drugs Aging."},{"key":"B18","first-page":"24","article-title":"et al. Electroconvulsive therapy: how modern techniques improve patient outcomes: refinements have decreased memory loss, other adverse effects while retaining efficacy: refinements have decreased memory loss, other adverse effects while retaining efficacy","volume":"11","author":"Tirmizi","year":"2012","journal-title":"Curr Psychiatr"},{"key":"B19","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1176\/appi.ajp.2020.177901","article-title":"The American psychiatric association practice guideline for the treatment of patients with schizophrenia","volume":"177","author":"Keepers","year":"2020","journal-title":"Am J Psychiatry."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.3892\/etm.2021.10659","article-title":"Antipsychotic polypharmacy in adult patients diagnosed with schizophrenia: a retrospective study","volume":"22","author":"Patrichi","year":"2021","journal-title":"Exp Ther Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1001\/jamapsychiatry.2017.0624","article-title":"Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence","volume":"74","author":"Correll","year":"2017","journal-title":"JAMA Psychiatry."},{"key":"B22","doi-asserted-by":"publisher","first-page":"30","DOI":"10.4103\/npmj.npmj_93_19","article-title":"Antipsychotic prescription and polypharmacy among outpatients with schizophrenia in a Nigerian hospital","volume":"27","author":"Anozie","year":"2020","journal-title":"Niger Postgrad Med J."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1177\/0269881118795333","article-title":"Antipsychotic drug use and pneumonia: Systematic review and meta-analysis","volume":"32","author":"Dzahini","year":"2018","journal-title":"J Psychopharmacol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1093\/schbul\/sbr202","article-title":"Second-generation antipsychotic medications and risk of pneumonia in schizophrenia","volume":"39","author":"Kuo","year":"2013","journal-title":"Schizophr Bull."},{"key":"B25","doi-asserted-by":"publisher","first-page":"20m02594","DOI":"10.4088\/PCC.20m02594","article-title":"Second-generation antipsychotics and pneumonia-related hospitalizations","volume":"22","author":"Milano","year":"2020","journal-title":"Prim Care Companion CNS Disord"},{"key":"B26","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.ajic.2017.09.005","article-title":"The epidemiology of nonventilator hospital-acquired pneumonia in the United States","volume":"46","author":"Giuliano","year":"2018","journal-title":"Am J Infect Control."},{"key":"B27","doi-asserted-by":"publisher","first-page":"CD006391","DOI":"10.1002\/14651858.CD006391.pub2","article-title":"Benzodiazepines for schizophrenia","volume":"11","author":"Dold","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1111\/j.1532-5415.2011.03586.x","article-title":"Use of opioids or benzodiazepines and risk of pneumonia in older adults: a population-based case-control study","volume":"59","author":"Dublin","year":"2011","journal-title":"J Am Geriatr Soc."},{"key":"B29","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1136\/thoraxjnl-2013-203211","article-title":"The impact of benzodiazepines on occurrence of pneumonia and mortality from pneumonia: a nested case-control and survival analysis in a population-based cohort","volume":"68","author":"Iqbal","year":"2013","journal-title":"Thorax."},{"key":"B30","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.1007\/s00213-018-5039-9","article-title":"Benzodiazepines and risk of pneumonia in schizophrenia: a nationwide case-control study","volume":"235","author":"Cheng","year":"2018","journal-title":"Psychopharmacology (Berl)."},{"key":"B31","doi-asserted-by":"publisher","first-page":"E519","DOI":"10.1503\/cmaj.160126","article-title":"Risk of pneumonia associated with incident benzodiazepine use among community-dwelling adults with Alzheimer disease","volume":"189","author":"Taipale","year":"2017","journal-title":"CMAJ."},{"key":"B32","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1002\/gps.5048","article-title":"Benzodiazepines or related drugs and risk of pneumonia: A systematic review and meta-analysis","volume":"34","author":"Sun","year":"2019","journal-title":"Int J Geriatr Psychiatry."},{"key":"B33","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3233\/JAD-180912","article-title":"Antiepileptic drug use is associated with an increased risk of pneumonia among community-dwelling persons with alzheimer's disease-matched cohort study","volume":"68","author":"Taipale","year":"2019","journal-title":"J Alzheimers Dis."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e79","DOI":"10.4088\/JCP.12m07938","article-title":"Antipsychotic drugs, mood stabilizers, and risk of pneumonia in bipolar disorder: a nationwide case-control study","volume":"74","author":"Yang","year":"2013","journal-title":"J Clin Psychiatry."},{"key":"B35","doi-asserted-by":"publisher","first-page":"701","DOI":"10.2147\/NDT.S62266","article-title":"Augmentation with antidepressants in schizophrenia treatment: benefit or risk","volume":"11","author":"Mao","year":"2015","journal-title":"Neuropsychiatr Dis Treat"},{"key":"B36","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.jclinepi.2006.11.022","article-title":"Observed association between antidepressant use and pneumonia risk was confounded by comorbidity measures","volume":"60","author":"Hennessy","year":"2007","journal-title":"J Clin Epidemiol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1800475","DOI":"10.1183\/13993003.00475-2018","article-title":"Serotonergic antidepressant use and morbidity and mortality among older adults with COPD","volume":"52","author":"Vozoris","year":"2018","journal-title":"Eur Respir J"},{"key":"B38","doi-asserted-by":"publisher","first-page":"740182","DOI":"10.3389\/fmed.2022.740182","article-title":"Antidepressants usage and risk of pneumonia among elderly patients with the parkinson's disease: a population-based case-control study","volume":"9","author":"Kuo","year":"2022","journal-title":"Front Med (Lausanne)."},{"journal-title":"Periodic safety update report sifrol no.12. 2009U09-001-01; Section 7.1.3; 2009 (Personal communication, Dr. Bartels, Boehringer Ingelheim).","year":"","author":"Dies","key":"B39"},{"key":"B40","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/1471-2377-12-113","article-title":"Pramipexole use and the risk of pneumonia","volume":"12","author":"Ernst","year":"2012","journal-title":"BMC Neurol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.5498\/wjp.v9.i1.1","article-title":"Electroconvulsive therapy: 80 years old and still going strong","author":"Gazdag","year":"2019","journal-title":"World J Psychiatry"},{"key":"B42","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.janh.2021.03.001","article-title":"The historical struggles of modified electroconvulsive therapy: how anesthesia came to the rescue","volume":"7","author":"Lava-Parmele","year":"2021","journal-title":"J Anesth Hist."},{"key":"B43","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1192\/bjp.99.414.148","article-title":"The routine use of muscular relaxants prior to electrical convulsive therapy","volume":"99","author":"ARDIS","year":"1953","journal-title":"J Ment Sci."},{"key":"B44","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/jgs.13932","article-title":"Anticholinergic medication use and risk of pneumonia in elderly adults: a nested case-control study","volume":"64","author":"Chatterjee","year":"2016","journal-title":"J Am Geriatr Soc."},{"key":"B45","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1080\/17512433.2019.1577134","article-title":"A comprehensive review of swallowing difficulties and dysphagia associated with antipsychotics in adults","volume":"12","author":"Cicala","year":"2019","journal-title":"Expert Rev Clin Pharmacol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3949\/ccjm.73.4.351","article-title":"Side effects of antidepressants: an overview","volume":"73","author":"Khawam","year":"2006","journal-title":"Cleve Clin J Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/s0025-6196(12)60643-0","article-title":"Problems with benzodiazepines in elderly patients","volume":"68","author":"Juergens","year":"1993","journal-title":"Mayo Clin Proc."},{"key":"B48","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1001\/archinte.159.17.2058","article-title":"Risk factors for pneumonia and other lower respiratory tract infections in elderly residents of long-term care facilities","volume":"159","author":"Loeb","year":"1999","journal-title":"Arch Intern Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1177\/1756285611417920","article-title":"The cognitive impact of antiepileptic drugs","volume":"4","author":"Eddy","year":"2011","journal-title":"Ther Adv Neurol Disord."},{"key":"B50","doi-asserted-by":"publisher","first-page":"e20129","DOI":"10.1097\/MD.0000000000020129","article-title":"Trihexyphenidyl induced malignant hyperthermia in a patient with Parkinson's disease complicated with pneumonia: A case report","volume":"99","author":"Zhao","year":"2020","journal-title":"Medicine (Baltimore)."},{"key":"B51","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1080\/07853890.2020.1840621","article-title":"IL-6 and other biomarkers as predictors of severity in COVID-19","volume":"53","author":"Broman","year":"2021","journal-title":"Ann Med."},{"key":"B52","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s12890-016-0324-z","article-title":"The balance between the serum levels of IL-6 and IL-10 cytokines discriminates mild and severe acute pneumonia","volume":"16","author":"de Brito","year":"2016","journal-title":"BMC Pulm Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1183\/09031936.00040710","article-title":"Factors associated with inflammatory cytokine patterns in community-acquired pneumonia","volume":"37","author":"Mart\u00ednez","year":"2011","journal-title":"Eur Respir J."},{"key":"B54","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.brs.2017.10.013","article-title":"Electroconvulsive therapy, depression, the immune system and inflammation: a systematic review","volume":"11","author":"Yrondi","year":"2018","journal-title":"Brain Stimul."},{"key":"B55","doi-asserted-by":"publisher","first-page":"113735","DOI":"10.1016\/j.psychres.2021.113735","article-title":"Cytokines changes associated with electroconvulsive therapy in patients with treatment-resistant depression: a Meta-analysis","volume":"297","author":"Gay","year":"2021","journal-title":"Psychiatry Res."},{"key":"B56","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1097\/YCT.0000000000000127","article-title":"The immune system and electroconvulsive therapy for depression","volume":"30","author":"Guloksuz","year":"2014","journal-title":"J ECT."},{"key":"B57","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/s0022-3956(00)00032-7","article-title":"Effects of antipsychotic drugs on cytokine networks","volume":"34","author":"Pollm\u00e4cher","year":"2000","journal-title":"J Psychiatr Res."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1097\/CCM.0b013e31827c0c8d","article-title":"Benzodiazepine augmented \u03b3-amino-butyric acid signaling increases mortality from pneumonia in mice","volume":"41","author":"Sanders","year":"2013","journal-title":"Crit Care Med."},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006570.pub3","article-title":"Benzodiazepines for catatonia in people with schizophrenia or other serious mental illnesses","author":"Zaman","year":"2019","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2022.1071079\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T05:13:20Z","timestamp":1673586800000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2022.1071079\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,13]]},"references-count":59,"alternative-id":["10.3389\/fpsyt.2022.1071079"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2022.1071079","relation":{},"ISSN":["1664-0640"],"issn-type":[{"type":"electronic","value":"1664-0640"}],"subject":[],"published":{"date-parts":[[2023,1,13]]},"article-number":"1071079"}}